New drug combo tested in fight against rapid ALS form
NCT ID NCT05508074
Summary
This study tested whether adding a new drug called IFB-088 to the standard medication riluzole could help people with a specific, rapidly progressing form of ALS that starts with speech and swallowing problems. 51 participants were randomly assigned to receive either IFB-088 or a placebo, along with riluzole, for six months. Researchers measured safety, changes in physical function, breathing ability, and quality of life to see if IFB-088 showed promise.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA
Marseille, 13385, France
-
CHU Bretonneau
Tours, 37044, France
-
CHU de Nantes - Hôpital Laennec
Nantes, 44093, France
-
CHU de Toulouse - Hôpital Pierre-Paul Riquet
Toulouse, 31059, France
-
Centro Clinico NeMO per le Malattie Neuromuscolari
Gussago, 25064, Italy
-
Hôpital Neurologique Pierre Wertheimer
Bron, 69677, France
-
IRCSS Istituto Neurologico Carlo Besta
Milan, 20133, Italy
-
Ospedale Civile Sant'Agostino Estense
Baggiovara, 41126, Italy
-
Sant'Andrea Hospital Unit of Neuromuscular Disorders
Roma, 00189, Italy
Conditions
Explore the condition pages connected to this study.